WEBINAR: Developing Innovative Compounds for Psychiatric& Neurological Conditions

4MTx is currently raising a final angel round and will be providing updates on the recent progress towards clinical trial initiation in Q1 2025. Join us on October 26th from 11am PDT (2 pm EST) to learn more about our lead program, pipeline, and platform from Founder/CEO/Director Pablo Lapuerta, MD, and Director Lawrence Goldstein, PhD.

4M Therapeutics Inc. (4MTx) is developing targeted therapies for the treatment of brain disorders by modulating key pathways associated with neuronal health. Their lead asset, 4MT2001, aims to replace lithium therapy by providing equal or better efficacy with a superior safety profile for bipolar disorder. Their pipeline has the potential to address Alzheimer’s disease, frontal temporal dementia, and other brain diseases with broad clinical, commercial, and partnering potential. 4MTx is currently raising a final angel round and will be providing updates on the recent progress towards clinical trial initiation in Q1 2025.